Alterity Therapeutics Limited (PBN) - Total Liabilities
Based on the latest financial reports, Alterity Therapeutics Limited (PBN) has total liabilities worth €3.62 Million EUR (≈ $4.24 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PBN operating cash flow to assess how effectively this company generates cash.
Alterity Therapeutics Limited - Total Liabilities Trend (2014–2025)
This chart illustrates how Alterity Therapeutics Limited's total liabilities have evolved over time, based on quarterly financial data. Check Alterity Therapeutics Limited liquidity resilience to evaluate the company's liquid asset resilience ratio.
Alterity Therapeutics Limited Competitors by Total Liabilities
The table below lists competitors of Alterity Therapeutics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
INTER RAO Lietuva AB
WAR:IRL
|
Poland | zł41.78 Million |
|
Tunas Alfin Tbk
JK:TALF
|
Indonesia | Rp583.40 Billion |
|
Zomedica Pharmaceuticals Corp
NYSE MKT:ZOM
|
USA | $10.55 Million |
|
Orient Bell Limited
NSE:ORIENTBELL
|
India | Rs1.98 Billion |
|
Kanpur Plastipack Limited
NSE:KANPRPLA
|
India | Rs2.14 Billion |
|
VirnetX Holding Corp Common Stock
NASDAQ:VHC
|
USA | $8.59 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Alterity Therapeutics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Alterity Therapeutics Limited market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alterity Therapeutics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alterity Therapeutics Limited (2014–2025)
The table below shows the annual total liabilities of Alterity Therapeutics Limited from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €3.62 Million ≈ $4.24 Million |
-33.22% |
| 2024-06-30 | €5.43 Million ≈ $6.34 Million |
+20.44% |
| 2023-06-30 | €4.50 Million ≈ $5.27 Million |
-23.57% |
| 2022-06-30 | €5.89 Million ≈ $6.89 Million |
+89.20% |
| 2021-06-30 | €3.12 Million ≈ $3.64 Million |
+13.00% |
| 2020-06-30 | €2.76 Million ≈ $3.22 Million |
-17.83% |
| 2019-06-30 | €3.36 Million ≈ $3.92 Million |
+26.86% |
| 2018-06-30 | €2.64 Million ≈ $3.09 Million |
+66.25% |
| 2017-06-30 | €1.59 Million ≈ $1.86 Million |
-32.53% |
| 2016-06-30 | €2.36 Million ≈ $2.76 Million |
-13.35% |
| 2015-06-30 | €2.72 Million ≈ $3.18 Million |
-31.19% |
| 2014-06-30 | €3.95 Million ≈ $4.62 Million |
-- |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-… Read more